APITBIO is a series a startup. 2 investors tracked. Status: possibledead.
APITBIO is a startup based in South Korea. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
APITBIO develops antibody-based therapeutics for cancer and chronic hepatitis B, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, leveraging human synthetic antibody libraries and production technologies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.